NCT03839459
- Conditions
- Blood Protein Disorders, Hematologic Diseases, Hemic and Lymphatic Diseases, +7 more
- Locations
-
- University of Rochester Rochester, New York, United States
Clinical trial condition
Smoldering Multiple Myeloma
Explore clinical trials studying Smoldering Multiple Myeloma. Study availability and eligibility vary by location and protocol.
44 public trials
15 recruiting studies
Smoldering Multiple Myeloma trial results
NCT03301220
- Conditions
- Blood Protein Disorders, Hematologic Diseases, Hemic and Lymphatic Diseases, +7 more
- Locations
-
- Arizona Oncology Associates, PC - HAL Phoenix, Arizona, United States
- Innovative Clinical Research Inc Whittier, California, United States
- Miami Cancer Institute Miami, Florida, United States
- Emory University Atlanta, Georgia, United States
NCT01222286
- Conditions
- Blood Protein Disorders, Hematologic Diseases, Hemic and Lymphatic Diseases, +7 more
- Locations
-
- Dana-Farber Cancer Institute Boston, Massachusetts, United States
- Mount Sinai School of Medicine New York, United States
- Ohio State University Columbus, Ohio, United States
- Hospital of the University of Pennsylvania Philadelphia, Pennsylvania, United States
Completed
Imaging in MGUS, SMM and MM
NCT01237054
- Conditions
- Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +16 more
- Locations
-
- National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States
Completed
Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma
NCT02916771
- Conditions
- Blood Protein Disorders, Hematologic Diseases, Hemic and Lymphatic Diseases, +7 more
- Locations
-
- Dana Farber Cancer Institute Boston, Massachusetts, United States
NCT00112827
- Conditions
- Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +19 more
- Locations
-
- City of Hope Medical Center Duarte, California, United States
NCT04615572
- Conditions
- Amyloidosis, Blood Protein Disorders, Hematologic Diseases, +16 more
- Locations
-
- University of California, Irvine Health Chao Family Comprehensive Cancer Center Orange, California, United States
- University of California, San Francisco San Francisco, California, United States
- University of Miami Sylvester Comprehensive Cancer Center Miami, Florida, United States
- Tufts Medical Center Boston, Massachusetts, United States
Completed
A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma
NCT02903381
- Conditions
- Blood Protein Disorders, Hematologic Diseases, Hemic and Lymphatic Diseases, +7 more
- Locations
-
- Dana Farber Cancer Institute Boston, Massachusetts, United States
NCT02279394
- Conditions
- Blood Protein Disorders, Hematologic Diseases, Hemic and Lymphatic Diseases, +8 more
- Locations
-
- Colorado Blood Cancer Institute Denver, Colorado, United States
- St Francis Hospital and Medical Center Hartford, Connecticut, United States
- University of Chicago Chicago, Illinois, United States
- Eastern Maine Medical Center Brewer, Maine, United States
NCT01302886
- Conditions
- Blood Protein Disorders, Hematologic Diseases, Hemic and Lymphatic Diseases, +7 more
- Locations
-
- Highlands Oncology Group Dept of Highlands Oncology Grp Fayetteville, Arkansas, United States
- H. Lee Moffitt Cancer Center & Research Institute SC - 3 Tampa, Florida, United States
- Emory University School of Medicine/Winship Cancer Institute Dept. of Hematology (2) Atlanta, Georgia, United States
- Indiana University Indiana Univ Indianapolis, Indiana, United States